Details of the Drug Combinations

General Information of This Drug (ID: DMHQV6R)

• Drug Name: GS-4059 (DMHQV6R)
• Synonyms: tirabrutinib; Tirabrutinib; 1351636-18-4; UNII-LXG44NDL2T; LXG44NDL2T; Tirabrutinib [INN]; ONO-4059(Free base); SCHEMBL14798454; MolPort-044-728-902; BDBM194087; ZINC72318699; AKOS030526437; CS-5676; HY-15771; US9199997, 9; F10085; (R)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one; 6-Amino-9-((3R)-1-(2-butynoyl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one; 8H-Purin-8-one,6-amino-7,9-dihydro-9-((3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl)-7-(4-phenoxyphenyl); 6-Amino-9-[(3R)-1-(2-butyno

Indication

B-cell lymphoma; ICD 11: 2A86; Status: Phase 2 [1]; Rheumatoid arthritis; ICD 11: FA20; Status: Phase 1 [2]

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GS-4059 + GS-9973	DCX7QR1	GS-9973	B-cell Malignancies	[3]
Idelalisib + GS-4059	DCIMVSI	Idelalisib	B-cell Malignancies	[3]
Idelalisib + GS-4059	DCM20AR	Idelalisib	Chronic Lymphocytic Leukemia	[4]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT02457598) Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
• [4] ClinicalTrials.gov (NCT02968563) Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)